Joint Venture18 Mar 2026, 03:16 pm
Zydus Lifesciences and Torrent Pharma to Co-market Innovative Semaglutide Injection in India
AI Summary
Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market. The agreement allows Zydus to manufacture and supply the product, while Torrent Pharma will co-market it under its brand name SEMBOLIC™. Zydus will market the product under its brand SEMAGLYN™, MASHEMA™ and ALTERME™. The formulation is designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance. The partnership aims to improve patient access to advanced GLP-1 therapies for metabolic disorders.
Key Highlights
- Zydus and Torrent Pharma sign licensing agreement to co-market Semaglutide Injection in India
- Zydus to manufacture and supply the product, Torrent Pharma to co-market it under its brand SEMBOLIC™
- Zydus to market the product under its brand SEMAGLYN™, MASHEMA™ and ALTERME™
- Formulation designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance
- Partnership aims to improve patient access to advanced GLP-1 therapies for metabolic disorders